| As Of | Filing | | Doc. | | Page | | Title | Docs. |
|---|
| | |  |
| 5/3/24 |  | S-1 | | | | 1 | | About This Prospectus | 8 |
| 6/29/23 | | 424B5 | | | | 1 | | About This Prospectus Supplement | 1 |
| 12/22/23 | | S-3 | | | | 1 | | Additional Information | 2 |
| 8/7/23 | | DEF 14A | | | | 1 | | Annual Report | 2 |
| 12/14/23 | | 10-K | | | | 1 | | Business | 1 |
| 5/3/24 | | S-1 | | | | 1 | | Cautionary Note Concerning Forward-Looking Statements | 7 |
| 8/9/23 | | 424B4 | | | | 1 | | Cautionary Note Regarding Forward-Looking Statements | 2 |
| 12/14/23 | | 10-K | | | | 1 | | Certain Relationships and Related Transactions, and Director Independence | 1 |
| | | | | | 1 | | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 1 |
| 8/7/23 | | DEF 14A | | | | 1 | | Charter | 2 |
| 12/14/23 | | 10-K | | | | 1 | | Commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, payors and others in the medical community, The | 1 |
| 5/3/24 | | S-1 | | | | 1 | | Committed Equity Financing, The | 1 |
| 6/29/23 | | 424B5 | | | | 1 | | Concurrent Private Placement of Warrants | 1 |
| 2/14/24 | | 10-Q | | | | 1 | | Consolidated Balance Sheets | 4 |
| | | | | | 1 | | Consolidated Statements of Cash Flows | 4 |
| 8/14/23 | | 10-Q | | | | 1 | | Consolidated Statements of Changes in Stockholders' (Deficit) Equity | 2 |
| 2/14/24 | | 10-Q | | | | 1 | | Consolidated Statements of Changes in Stockholders' Equity (Deficit) | 4 |
| | | | | | 1 | | Consolidated Statements of Operations | 4 |
| | | | | | 1 | | Controls and Procedures | 4 |
| 8/7/23 | | DEF 14A | | | | 1 | | Corporate Governance Matters | 2 |
| 2/14/24 | | 10-Q | | | | 1 | | Defaults Upon Senior Securities | 3 |
| 5/3/24 | | S-1 | | | | 1 | | Description of Capital Stock | 8 |
| 12/22/23 | | S-3 | | | | 1 | | Description of Debt Securities | 2 |
| 8/9/23 | | 424B4 | | | | 1 | | Description of Securities | 2 |
| 10/26/23 | | 424B4 | | | | 1 | | Description of Securities We Are Offering | 5 |
| 12/22/23 | | S-3 | | | | 1 | | Description of Stock Warrants | 2 |
| | | | | | 1 | | Description of Subscription Rights | 2 |
| 6/29/23 | | 424B5 | | | | 1 | | Description of the Securities We Are Offering | 1 |
| 12/22/23 | | S-3 | | | | 1 | | Description of Units | 2 |
| 5/3/24 | | S-1 | | | | 1 | | Determination of Offering Price | 1 |
| 10/26/23 | | 424B4 | | | | 1 | | Dilution | 6 |
| 8/7/23 | | DEF 14A | | | | 1 | | Director Compensation | 2 |
| 12/14/23 | | 10-K | | | | 1 | | Directors, Executive Officers and Corporate Governance | 1 |
| 6/29/23 | | 424B5 | | | | 1 | | Disclosure of Commission Position on Indemnification for Securities Act Liabilities | 1 |
| | | | | | 1 | | Dividend Policy | 1 |
| 12/14/23 | | 10-K | | | | 1 | | Executive Compensation | 6 |
| 8/7/23 | | DEF 14A | | | | 1 | | Executive Officers | 2 |
| 8/21/23 | | S-8 | | | | 1 | | Exhibit Index | 1 |
| 2/14/24 | | 10-Q | | | | 1 | | Exhibits | 4 |
| 5/3/24 | | S-1 | | | | 1 | | Exhibits and Financial Statements Schedules | 1 |
| 12/14/23 | | 10-K | | | | 1 | | Exhibits, Financial Statement Schedules | 1 |
| 5/3/24 | | S-1 | | | | 1 | | Experts | 10 |
| 2/14/24 | | 10-Q | | | | 1 | | Financial Information | 3 |
| | | | | | 1 | | Financial Statements (unaudited) | 3 |
| 12/14/23 | | 10-K | | | | 1 | | Financial Statements and Supplementary Data | 1 |
| | | | | | 1 | | Form 10-K Summary | 1 |
| 12/22/23 | | S-3 | | | | 1 | | Forms of Securities | 2 |
| | | | | | 1 | | Forward-Looking Statements | 2 |
| 8/7/23 | | DEF 14A | | | | 1 | | General Information | 2 |
| | | | | | 1 | | Householding of Annual Meeting Materials | 2 |
| 6/29/23 | | 424B5 | | | | 1 | | Incorporation of Certain Documents by Reference | 1 |
| 12/22/23 | | S-3 | | | | 1 | | Incorporation of Certain Information by Reference | 2 |
| 8/21/23 | | S-8 | | | | 1 | | Incorporation of Documents by Reference | 1 |
| 5/3/24 | | S-1 | | | | 1 | | Indemnification of Directors and Officers | 1 |
| | | | | | 1 | | Information Incorporated by Reference | 8 |
| | | | | | 1 | | Legal Matters | 10 |
| 2/14/24 | | 10-Q | | | | 1 | | Legal Proceedings | 4 |
| | | | | | 1 | | Management's Discussion and Analysis of Financial Condition and Results of Operations | 4 |
| 12/14/23 | | 10-K | | | | 1 | | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 1 |
| 2/14/24 | | 10-Q | | | | 1 | | Mine Safety Disclosures | 4 |
| 12/14/23 | | 10-K | | | | 1 | | Notes to Consolidated Financial Statements | 1 |
| 2/14/24 | | 10-Q | | | | 1 | | Notes to Interim Consolidated Financial Statements | 3 |
| 5/3/24 | | S-1 | | | | 1 | | Offering, The | 7 |
| | | | | | 1 | | Other Expenses of Issuance and Distribution | 1 |
| 2/14/24 | | 10-Q | | | | 1 | | Other Information | 4 |
| 8/7/23 | | DEF 14A | | | | 1 | | Other Matters | 2 |
| 8/21/23 | | S-8 | | | | 1 | | Part I Explanatory Note | 1 |
| | | | | | 1 | | Part Ii Information Required in the Registration Statement | 1 |
| 5/3/24 | | S-1 | | | | 1 | | Plan of Distribution | 5 |
| 9/19/23 | | S-1 | | | | 1 | | Power of attorney (included in the signature page to this registration statement) | 2 |
| 5/3/24 | | S-1 | | | | 1 | | Power of attorney (included in the signature page) | 1 |
| 8/21/23 | | S-8 | | | | 1 | | Power of Attorney (included on the signature page to this registration statement on Form S-8) | 1 |
| 12/22/23 | | S-3 | | | | 1 | | Power of Attorney (included on the signature page) | 2 |
| 12/14/23 | | 10-K | | | | 1 | | Principal Accounting Fees and Services | 1 |
| | | | | | 1 | | Properties | 1 |
| 8/7/23 | | DEF 14A | | | | 1 | | Proposal 1: to Elect Six Directors to the Board of Directors to Hold Office for the Following Year Until Their Successors Have Been Duly Elected and Qualified | 2 |
| | | | | | 1 | | Proposal 3: Ratification of the Appointment of Our Registered Public Accounting Firm | 2 |
| 5/3/24 | | S-1 | | | | 1 | | Prospectus Summary | 8 |
| 2/14/24 | | 10-Q | | | | 1 | | Quantitative and Qualitative Disclosures about Market Risk | 4 |
| 5/3/24 | | S-1 | | | | 1 | | Recent Sales of Unregistered Securities | 1 |
| 12/14/23 | | 10-K | | | | 1 | | Report of Independent Registered Public Accounting Firm | 1 |
| 8/7/23 | | DEF 14A | | | | 1 | | Report of the Audit Committee | 2 |
| 5/3/24 | | S-1 | | | | 1 | | Risk Factors | 14 |
| 12/22/23 | | S-3 | | | | 1 | | Securities We May Offer, The | 2 |
| 8/7/23 | | DEF 14A | | | | 1 | | Security Ownership of Certain Beneficial Owners and Management | 2 |
| 12/14/23 | | 10-K | | | | 1 | | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 1 |
| 5/3/24 | | S-1 | | | | 1 | | Selling Securityholder | 1 |
| 8/9/23 | | 424B4 | | | | 1 | | Selling Stockholders | 2 |
| 2/14/24 | | 10-Q | | | | 1 | | Signatures | 4 |
| 8/7/23 | | DEF 14A | | | | 1 | | Stockholder Proposals | 2 |
| 8/9/23 | | 424B4 | | | | 1 | | Summary | 3 |
| 12/14/23 | | 10-K | | | | 1 | | The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, payors and others in the medical community | 1 |
| 5/3/24 | | S-1 | | | | 1 | | The Committed Equity Financing | 1 |
| | | | | | 1 | | The Offering | 7 |
| 12/22/23 | | S-3 | | | | 1 | | The Securities We May Offer | 2 |
| 8/7/23 | | DEF 14A | | | | 1 | | Transactions With Related Persons | 2 |
| 5/3/24 | | S-1 | | | | 1 | | Undertakings | 1 |
| 10/26/23 | | 424B4 | | | | 1 | | Underwriting | 5 |
| 2/14/24 | | 10-Q | | | | 1 | | Unregistered Sales of Equity Securities and Use of Proceeds | 2 |
| 5/10/23 | | 10-Q | | | | 1 | | Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities | 1 |
| 12/14/23 | | 10-K | | | | 1 | | Unresolved Staff Comments | 1 |
| 5/3/24 | | S-1 | | | | 1 | | Use of Proceeds | 10 |
| | | | | | 1 | | Where You Can Find More Information | 9 |
